Stories from news aggregators
- Field Notes #4: Resilient Refiles, Definium’s Readout, HRSA’s RFI Responses, and J&J’s Neuroplastogen Bet
- Credentials, Clinics, and Costs: Stakeholders Respond to HRSA’s Psychedelic Therapy RFI
- Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C
- Paving the Way: Husseini Manji on Spravato’s Lessons for Psychedelic Drug Development
- The Psychedelic Practitioner Issue 6: Preparedness (People)
- Two Years After Rejection, Resilient Quietly Refiles MDMA for PTSD Application
- Smooth Sailing: Definium’s LSD Voyage Hits Primary and Key Secondary Endpoints in GAD
- Pα+ Psychedelic Bulletin #229: SAMHSA Convenes Experts; AtaiBeckley’s Road to Lilly; Turnbull Doubles Down on BOL-148; Compass Talks Indication Expansion, Could VA Help?
- From Sonora to Big Pharma: Kimon de Greef Traces the Strange Rise of 5-MeO-DMT
- Psychedelic Alpha Crossword: Summer 2026
- Beyond the Biological Baseline: Dr. Grace Blest-Hopley on Developing Female-Inclusive Psychedelic Frameworks
- Q1 2026: Oregon Psilocybin Services Update
- Psychedelic Funding Update: Q2 2026
- Pα+ Psychedelic Bulletin #228: Inside the Lilly-Atai Deal; An Update on the GH-AtaiBeckley Patent Standoff; Field Reacts to FDA’s Guidance; Resilient Readies Resubmission
- Q3’26 Psychedelic Drug Development Pipeline: Bullseye Charts
Articles from psychedelic websites/publications
- Field Notes #4: Resilient Refiles, Definium’s Readout, HRSA’s RFI Responses, and J&J’s Neuroplastogen Bet
- Credentials, Clinics, and Costs: Stakeholders Respond to HRSA’s Psychedelic Therapy RFI
- Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C
- Paving the Way: Husseini Manji on Spravato’s Lessons for Psychedelic Drug Development
- The Psychedelic Practitioner Issue 6: Preparedness (People)
- Two Years After Rejection, Resilient Quietly Refiles MDMA for PTSD Application
- Smooth Sailing: Definium’s LSD Voyage Hits Primary and Key Secondary Endpoints in GAD
- Pα+ Psychedelic Bulletin #229: SAMHSA Convenes Experts; AtaiBeckley’s Road to Lilly; Turnbull Doubles Down on BOL-148; Compass Talks Indication Expansion, Could VA Help?
- From Sonora to Big Pharma: Kimon de Greef Traces the Strange Rise of 5-MeO-DMT
- Psychedelic Alpha Crossword: Summer 2026
- Beyond the Biological Baseline: Dr. Grace Blest-Hopley on Developing Female-Inclusive Psychedelic Frameworks
- Q1 2026: Oregon Psilocybin Services Update
- Psychedelic Funding Update: Q2 2026
- Pα+ Psychedelic Bulletin #228: Inside the Lilly-Atai Deal; An Update on the GH-AtaiBeckley Patent Standoff; Field Reacts to FDA’s Guidance; Resilient Readies Resubmission
- Q3’26 Psychedelic Drug Development Pipeline: Bullseye Charts